Feb 11, 2026 · Schrödinger is the scientific leader in developing state-of-the-art chemical simulation software for use in pharmaceutical, biotechnology, and materials research.

Our mission is to improve human health and quality of life by transforming the way therapeutics and materials are discovered.

Our physics-based computational platform integrates differentiated solutions for predictive modeling, data analytics, and collaboration to enable rapid exploration of chemical space.

Headquartered in New York City, Schrödinger has multiple offices around the world including the USA, the UK, Germany, India, and Japan.

Schrödinger’s collaborative leadership team is committed to achieving the best possible outcomes for our customers, partners, patients, and other stakeholders.

Jan 12, 2026 · Schrdinger, Inc. (Nasdaq: SDGR) provided an update on its progress across the business in 2025 and announced its strategic priorities for 2026. The company is continuing to focus on …

We are leveraging our computational platform and massive computing power to advance our proprietary programs both independently and in collaboration with leading biotech and pharmaceutical companies.

Jan 9, 2026 · Schrödinger is transforming the way therapeutics and materials are discovered. Learn more about our company.

Dec 17, 2025 · 難溶性薬物の放出メカニズムを解明する – ASD研究の新たなアプローチ | Modelling amorphous solid dispersion (ASD) release mechanisms OCT 15, 2025 | AbbVie と Schrödinger のエ …

Sep 30, 2025 · NEW YORK-- (BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR) today announced financial results for the quarter ended September 30, 2025. "Schrödinger delivered a solid third …